SHORT-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH INSULIN IN INSULIN-NAIVE SUBJECTS WITH TYPE 2 DIABETES IN SWEDEN

被引：1
|
作者：
Ridderstrale, M. [1 ,2 ]
Ericsson, A. [3 ]
Jensen, M. M. [4 ]
机构：
[1] Skane Univ Hosp, Dept Endocrinol, Malmo, Sweden
[2] Univ Lund Hosp, Dept Clin Sci, Malmo, Sweden
[3] Novo Nordisk Scandinavia AB, Malmo, Sweden
[4] Novo Nordisk Scandinavia AB, Copenhagen, Denmark
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1351
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A480 / A480
页数：1
相关论文
共 50 条
  • [11] Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach
    Pollock, Richard F.
    Chubb, Barrie
    Valentine, William J.
    Heller, Simon
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2018, 11 : 217 - 226
  • [12] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis
    Tunis, Sandra L.
    Minshall, Michael E.
    Conner, Christopher
    McCormick, John I.
    Kapor, Jovana
    Yale, Jean-Francois
    Groleau, Danielle
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) : 1273 - 1284
  • [13] COST-EFFECTIVENESS OF INSULIN DETEMIR IN PEOPLE WITH TYPE 2 DIABETES IN ROMANIA
    Ionescu-Targoviste, C.
    Wrona, W.
    Schubert, A.
    Niewada, M.
    Czech, M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
  • [14] SHORT AND LONG-TERM COST-EFFECTIVENESS OF SWITCHING THERAPY FROM INSULIN GLARGINE TO INSULIN DETEMIR IN PEOPLE WITH TYPE 2 DIABETES
    Malek, R.
    Galvez, G. G.
    Hammerby, E.
    Nikolajsen, A.
    Henriksen, O.
    Andersen, M. F. B.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A690 - A690
  • [15] Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK
    McEwan, Phil
    Poole, Chris D.
    Tetlow, Tony
    Holmes, Paul
    Currie, Craig J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S7 - S19
  • [16] Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective
    Permsuwan, Unchalee
    Thavorn, Kednapa
    Dilokthornsakul, Piyameth
    Saokaew, Surasak
    Chaiyakunapruk, Nathorn
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (09) : 991 - 999
  • [17] An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes
    Shafie, Asrul Akmal
    Gupta, Vishal
    Baabbad, Ranya
    Hammerby, Eva
    Home, Philip
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 (02) : 319 - 327
  • [18] Short-term Effects of NPH Insulin, Insulin Detemir, and Insulin Glargine on the IGF-IGFBP-GH Axis in Patients with Type 1 Diabetes
    Frystyk, Jan
    Ma, Zhulin
    Laursen, Torben
    Lauritzen, Torsten
    Christiansen, Jens S.
    [J]. DIABETES, 2014, 63 : A489 - A490
  • [19] Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naive Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
    Shafie, Asrul Akmal
    Ng, Chin Hui
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 333 - 343
  • [20] The relative cost effectiveness of switching to insulin glargine versus NPH insulin in insulin naive and non insulin naive type 2 diabetes patients using UK real life data
    McEwan, P.
    Mehin, N.
    Tetlow, A. P.
    Sharplin, P.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A223 - A223
12345